These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
Eli Lilly (NYSE: LLY) and (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat.
Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review. And while the recently released phase 3 clinical trial data for Lilly's candidate looks promising, it too has a record of swinging and missing.
So is the high likelihood of an Alzheimer's market showdown going to make or break one of these two titans? It isn't likely. In fact, both could flourish -- but one might flourish more than the other. Here's why.
Source Fool.com
Biogen Inc. Aktie
195,20 €
-1,85 %
Die Community bevorzugt klar Biogen Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Ein Kursziel von 289 € für Biogen Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 195.2 € bedeuten.
